Nigerian biotech startup Syndicate Bio has announced a strategic partnership with the National Institute for Cancer Research and Treatment (NICRAT) to initiate the Cancer Genome Nigeria project, a study aimed at bridging cancer disparity gaps by studying the most prevalent cancers across Nigeria’s six geopolitical zones and more than 300 ethnolinguistic groups. The company’s strategic partnership with NICRAT will be a coordinated project to address cancer diagnosis and treatment for patients in Nigeria. Through this project, the availability and accessibility of next-generation sequencing (NGS) based cancer tests in the country, would pave the way for more targeted therapeutics for patients in Nigeria. “The disparities in cancer care in Nigeria and across Africa, represent an ecosystem challenge that demands tailored solutions. This is why our partnership with NICRAT is important for the advancement of cancer research and treatment outcomes in Nigeria, the impact of which will be felt across the world through the inclusion of diverse genomes in global cancer research.
